Deborah Layton, FISPE FRPharmS PhD

Principal and Drug Safety Lead, Health Analytics
Lane Clark & Peacock (LCP) LLP , UK, United Kingdom

Poster(s):

• (A-201) An evidence base to support the establishment of a fit-for-purpose quality management system for secondary data pharmacoepidemiological studies
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-206) Assessing Core Competencies in Pharmacoepidemiology Training Programs: A Global Needs Assessment
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-349) Assessing the Association Between COVID-19 Vaccination and Thrombotic Thrombocytopenia Syndrome (ATTEST Study): Analyses of English Data, 2020–2022
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (SLC-018) Enhancing Pregnancy Drug Safety Studies: Expert Consensus on Methods and Definitions
  Tuesday, August 26, 2025

  12:15 PM - 1:15 PM ET

• (C-163) Harmonizing Standards: Recommendations for Mitigating Gaps in Real-World Evidence (RWE) Feasibility Guidance
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (SLC-053) Risk of Venous Thrombosis With Thrombocytopenia Syndrome After Vaccination With AZD1222: A European VAC4EU Post-Authorisation Safety Study
  Tuesday, August 26, 2025

  12:15 PM - 1:15 PM ET

• (A-356) Safety Profile of Vaxzevria® COVID-19 Vaccine in the COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER)
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET